STOCK TITAN

Aspira Women’s Health Issues Letter to Shareholders and Announces Virtual Research & Development Day on October 29, 2024

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Positive)
Tags

Aspira Women's Health (Nasdaq: AWH) announced it has been awarded $10 million over two years from the Advanced Research Projects Agency for Health (ARPA-H) as part of the Sprint for Women's Health initiative. The funding will support the development of ENDOinform™, a multi-marker blood test for endometriosis detection using AI-enabled algorithms combining protein and microRNA biomarkers. Selected as one of 23 awardees from over 1,700 submissions, Aspira received one of only six Launchpad awards for advanced-stage projects. The company expects to meet its first milestone in Q4 2024, triggering a $2 million payment. The company will host a virtual R&D Day on October 29, 2024, to discuss the development pipeline.

Aspira Women's Health (Nasdaq: AWH) ha annunciato di aver ricevuto un finanziamento di 10 milioni di dollari in due anni dall'Advanced Research Projects Agency for Health (ARPA-H) nell'ambito dell'iniziativa Sprint for Women's Health. Il finanziamento supporterà lo sviluppo di ENDOinform™, un test ematico multi-marcatore per la rilevazione dell'endometriosi che utilizza algoritmi abilitati all'IA che combinano biomarcatori proteici e microRNA. Selezionata come uno dei 23 vincitori tra oltre 1.700 candidature, Aspira ha ricevuto uno dei soli sei premi Launchpad per progetti in fase avanzata. L'azienda prevede di raggiungere il suo primo traguardo nel Q4 2024, attivando un pagamento di 2 milioni di dollari. L'azienda ospiterà un R&D Day virtuale il 29 ottobre 2024, per discutere del pipeline di sviluppo.

Aspira Women's Health (Nasdaq: AWH) anunció que ha sido galardonada con 10 millones de dólares durante dos años por parte de la Advanced Research Projects Agency for Health (ARPA-H) como parte de la iniciativa Sprint for Women's Health. La financiación apoyará el desarrollo de ENDOinform™, un análisis de sangre multi-marcador para la detección de endometriosis que utiliza algoritmos habilitados por IA que combinan biomarcadores de proteínas y microARN. Seleccionada como uno de los 23 beneficiarios entre más de 1,700 presentaciones, Aspira recibió uno de los seis premios Launchpad para proyectos en etapa avanzada. La compañía espera alcanzar su primer hito en el cuarto trimestre de 2024, lo que desencadenará un pago de 2 millones de dólares. La empresa organizará un Día de I+D virtual el 29 de octubre de 2024 para discutir el pipeline de desarrollo.

아스피라 여성 건강 (Nasdaq: AWH)는 건강을 위한 첨단 연구 프로젝트 기관(ARPA-H)으로부터 여성 건강 스프린트 이니셔티브의 일환으로 2년 동안 1천만 달러를 지원받았다고 발표했습니다. 이 자금은 단백질 및 마이크로RNA 바이오마커를 결합한 AI 지원 알고리즘을 사용하여 자궁내막증을 탐지하기 위한 다중 마커 혈액 검사인 ENDOinform™의 개발을 지원할 것입니다. 1,700건 이상의 제출물 중 23명의 수상자로 선정된 아스피라는 고급 프로젝트에 대한 Launchpad 상 중 6개 중 하나를 수상했습니다. 이 회사는 2024년 4분기에 첫 번째 이정표를 달성할 것으로 예상하며, 이로 인해 200만 달러의 지급이 발생합니다. 2024년 10월 29일에 개발 파이프라인에 대한 논의를 위해 가상 R&D 데이를 개최할 예정입니다.

Aspira Women's Health (Nasdaq: AWH) a annoncé avoir reçu 10 millions de dollars sur deux ans de l'Advanced Research Projects Agency for Health (ARPA-H) dans le cadre de l'initiative Sprint for Women's Health. Ce financement soutiendra le développement de ENDOinform™, un test sanguin à multiples marqueurs pour la détection de l'endométriose utilisant des algorithmes basés sur l'IA combinant des biomarqueurs protéiques et des microARN. Sélectionnée comme l'un des 23 lauréats parmi plus de 1 700 soumissions, Aspira a reçu l'un des six prix Launchpad pour les projets avancés. L'entreprise s'attend à atteindre son premier jalon au quatrième trimestre 2024, déclenchant un paiement de 2 millions de dollars. L'entreprise organisera une journée virtuelle de R&D le 29 octobre 2024 pour discuter de son pipeline de développement.

Aspira Women's Health (Nasdaq: AWH) gab bekannt, dass sie im Rahmen der Initiative Sprint for Women's Health von der Advanced Research Projects Agency for Health (ARPA-H) einen Zuschuss von 10 Millionen Dollar über zwei Jahre erhalten hat. Die Finanzierung wird die Entwicklung von ENDOinform™ unterstützen, einem Multi-Marker-Bluttest zur Erkennung von Endometriose, der KI-gestützte Algorithmen zur Kombination von Protein- und MikroRNA-Biomarkern verwendet. Aspira wurde als eines von 23 ausgezeichneten Unternehmen aus über 1.700 Einreichungen ausgewählt und erhielt einen der nur sechs Launchpad-Preise für Projekte in fortgeschrittener Phase. Das Unternehmen erwartet, im vierten Quartal 2024 seinen ersten Meilenstein zu erreichen, was eine Zahlung von 2 Millionen Dollar auslösen wird. Am 29. Oktober 2024 plant das Unternehmen, einen virtuellen R&D-Tag abzuhalten, um über die Entwicklungs-Pipeline zu diskutieren.

Positive
  • Secured $10 million ARPA-H funding over two years for ENDOinform development
  • First milestone payment of $2 million expected in Q4 2024
  • Selected as one of only six Launchpad awards from 1,700+ submissions
  • Access granted to ARPA-H expert advisors for product development support
Negative
  • None.

Insights

The $10 million ARPA-H award represents a significant milestone for Aspira Women's Health, particularly given its current market cap of $15.6 million. The first milestone payment of $2 million expected in Q4 2024 will provide important near-term funding. The selection from over 1,700 submissions and being one of only six Launchpad awards demonstrates strong validation of AWH's technology and commercial potential.

The endometriosis diagnostic market represents a substantial opportunity, with 6 million affected women in the US alone. The current diagnostic paradigm requiring invasive laparoscopic surgery creates a clear market need that ENDOinform™ could address. The government backing and access to expert resources significantly de-risks the development pathway.

The development of ENDOinform™ represents a potential breakthrough in endometriosis diagnostics. The current 7-10 year diagnosis delay and reliance on invasive procedures creates a significant unmet medical need. The test's AI-enabled algorithm combining protein and microRNA biomarkers leverages proven technology from their ovarian cancer tests, increasing probability of success.

The ARPA-H award provides not just funding but critical access to subject matter experts and advisors, significantly enhancing development capabilities. The two-year timeline to commercial launch is ambitious but achievable given the company's existing infrastructure and experience with similar diagnostic tools.

Event to feature presentations from Dr. Kevin Elias, Dr. Richard Gersh, Dr. Sandra Milligan, and Dr. Todd Pappas on the Company’s development pipeline

AUSTIN, Texas, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, has issued a letter to Company shareholders and announced it will host a virtual Research & Development Day on Tuesday, October 29, 2024, at 3:00 pm ET.

The R&D Day will highlight the company’s plans for its miRNA development pipeline, including the recently announced award from the Advanced Research Project Agency for Health (ARPA-H)’s Sprint for Women’s Health initiative for ENDOinform™. Details for the event are as follows:

Date:October 29, 2024
Time:3:00 pm ET
To register:Click HERE

For those who are unable to attend the live event, a replay will be available on the Events & Presentations portion of the Investor section on the Company’s website at www.Aspirawh.com.

Additionally, the Company issued the following letter to Company shareholders.

October 24, 2024

Dear Shareholder,

Yesterday, it was my honor to share news of an exciting development that we believe will shape Aspira Women’s Health for many years to come. We have been selected by the Advanced Research Projects Agency for Health (ARPA-H) as an awardee of the Sprint for Women’s Health, an initiative to address critical unmet challenges in women’s health, champion transformative innovations, and tackle health conditions that uniquely or disproportionately affect women. The contract was awarded as part of the White House Initiative on Women’s Health Research announced by First Lady Dr. Jill Biden.

Under this initiative, we were awarded $10 million in funding over two years to develop our multi-marker blood test to aid in the detection of endometriosis. Our test will rely on a powerful, AI-enabled algorithm that combines protein and microRNA biomarkers and patient data, and leverage technology that we pioneered for our ovarian cancer risk assessment blood tests. The endometriosis test, which was previously known by its project name EndoMDx, is being rebranded today as ENDOinform™.

The award defines a series of project milestones, the first of which we expect to meet in the fourth quarter of 2024. Upon successful acceptance of the required information related to the first milestone, Aspira will receive a payment of $2 million. The award also provides for access to a team of world-class subject matter experts and advisors to support the successful completion and commercial launch of the test before the end of the two-year contract term. We will work with an ARPA-H Program Manager and the ARPA-H Investor Catalyst Hub in the design, development, and commercial launch of this first-of-its kind test.

Aspira was selected as one of 23 awardees from a field of over 1,700 submissions. Most of these awards were given to early-stage projects. Aspira received one of only six Launchpad awards given to advanced-stage projects submitted by mature organizations with end-to-end product development capabilities. Aspira’s $10 million allocation was among the largest awards approved under the program, reflecting both our capabilities and the urgency of unmet medical needs related to endometriosis.

Endometriosis is a devastating, chronic gynecologic condition that affects as many as six million women in the United States alone. The lives of these women are impacted medically, economically, and socially. Many experience intense pain, starting as early as 12 years old, resulting in chronic absences from work or school. Women with endometriosis also have an increased risk of infertility and certain cancers. Moreover, the disease costs the American economy billions of dollars in lost productivity and healthcare expense each year.

Currently, this condition can only be identified through laparoscopic surgery. Many women face repeated invasive procedures over the course of their lives, with most women remaining undiagnosed for 7 to 10 years. ENDOinform is poised to radically change the diagnostic paradigm.

This is an incredible achievement and validation of Aspira’s capabilities. We have worked tirelessly to advance endometriosis diagnostic research for many years, but our strong scientific foundation alone would not have resulted in our success. We believe the intense focus on operational excellence and the rebuilding of our commercial capabilities over the past year were also instrumental in our selection. Our experienced and passionate cross-functional team came together to present a vision for ENDOinform that clearly impressed the selection committee. I am extraordinarily proud of both the effort and success.

Now the hard work really begins! We will work with the ARPA-H team to perform an assessment and detailed analysis of execution risks. Dr. Sandra Milligan, President, and Dr. Todd Pappas, Vice President of Research & Development, will leverage their extensive experience successfully leading similar projects as the executive sponsors of the project. They will be supported by Michelle Snider, who will step into a newly created Senior Vice President of Product Commercialization and Innovation role by the end of the year. I have begun a search for a Chief Commercial Officer to lead the sales and marketing organization Michelle has expanded and improved since joining Aspira last year.

Rest assured, we will not lose sight of our growth goals for our existing portfolio. Our commercial capabilities were an important element of our ARPA-H proposal and the successful scaling of the OvaSuiteSM tests will help us to drive adoption of the endometriosis product upon its completion.

We plan to review the program in more detail during a virtual Investor Day presentation on October 29th at 3:00 p.m. ET. Drs. Milligan and Pappas will share elements of our successful presentation and provide more details about the project. Investors can register using this link.

I want to thank you, our shareholders, for your support and commitment as this achievement would not have been possible without you. Our journey so far has had its challenges. You did not give up on us, and for that, I am deeply grateful.

On behalf of everyone on Team Aspira, and the millions of women who will benefit from our endometriosis test, thank you.

Sincerely,

Nicole Sandford
Chief Executive Officer

About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. is dedicated to the discovery, development, and commercialization of non-invasive, AI-powered tests to aid in the diagnosis of gynecologic diseases.

OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer risk for the 1.2+ million American women diagnosed with an adnexal mass each year. OvaWatch provides a negative predictive value of 99% and is used to assess ovarian cancer risk for women where initial clinical assessment indicates the mass is indeterminate or benign, and thus surgery may be premature or unnecessary. Ova1Plus is comprised of two FDA-cleared tests, Ova1® and Overa®, to assess the risk of ovarian malignancy in patients with adnexal masses planned for surgery.

Our in-development test pipeline will expand our ovarian cancer portfolio and address the tremendous need for non-invasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, we intend to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, we have developed the first-ever non-invasive test designed to identify endometriomas, one of the most commonly occurring forms of severe endometriosis. Through our ongoing endometriosis development program, we are combining microRNA and protein biomarkers with patient data, with the intent of identifying all endometriosis independent of disease location or severity.

Forward-Looking Statements
This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve a number of risks and uncertainties. Such forward-looking statements include statements regarding, among other things, the timing and completion of any products in the pipeline development and other statements that are predictive in nature. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as “designed to,” “expect,” “plan,” “anticipate,” “could,” “may,” “intend,” “will,” “continue,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this press release and other factors that may cause such differences include the satisfaction of customary closing conditions related to the offering and the expected timing of the closing of the offering. These and additional risks and uncertainties are described more fully in the company’s filings with the SEC, including those factors identified as “Risk Factors” in our most recent Annual Report on Form 10-K, for the fiscal year ended December 31, 2023, and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Aspira presently does not know, or that Aspira currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Aspira’s expectations, plans, or forecasts of future events and views as of the date of this press release. Subsequent events and developments may cause the Company’s assessments to change. However, while Aspira may elect to update these forward-looking statements at some point in the future, Aspira expressly disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Aspira’s assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Investor Relations Contact: 
Jamie Sullivan
Director of Corporate Communications
Investors@aspirawh.com


FAQ

What is the value of ARPA-H funding awarded to Aspira Women's Health (AWH)?

Aspira Women's Health (AWH) was awarded $10 million in funding over two years from ARPA-H's Sprint for Women's Health initiative.

When will Aspira Women's Health (AWH) host its R&D Day in 2024?

Aspira Women's Health will host a virtual R&D Day on October 29, 2024, at 3:00 pm ET.

What is ENDOinform by Aspira Women's Health (AWH)?

ENDOinform is a multi-marker blood test being developed by Aspira Women's Health that uses AI-enabled algorithms combining protein and microRNA biomarkers for endometriosis detection.

When will Aspira Women's Health (AWH) receive its first milestone payment for ENDOinform?

Aspira expects to meet its first milestone in Q4 2024, which will trigger a $2 million payment upon successful acceptance.

Aspira Women's Health Inc.

NASDAQ:AWH

AWH Rankings

AWH Latest News

AWH Stock Data

11.24M
11.07M
30.94%
13.89%
3.35%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States of America
AUSTIN